Impact of Regular Home Use of Lumoral Dual-light Photodynamic Therapy on Plaque Control and Gingival Health
Launched by KOITE HEALTH OY · Apr 29, 2022
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
Dental plaque triggers changes in gingival health, which results in slight swelling and bleeding from the gingival margin and causes gingivitis. Supragingival dental biofilm control can be achieved by mechanical and chemical means. Toothbrushing is effective in reducing levels of dental plaque (van der Weijden \& Slot 2015). It removes plaque from flat, accessible surfaces but is less effective at the gingival margins and in approximal areas, where the accumulation of residual plaque encourages gingivitis and deterioration of periodontal health. Effective toothbrushing is also depending on ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years old
- • Agreement to participate in the study and to sign a written consent form
- Exclusion Criteria:
- • Presence of any physical limitation or restriction that might restrict Lumoral use
- • Pregnancy or lactation
About Koite Health Oy
Koite Health Oy is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and development. Based in Finland, the company specializes in designing and managing clinical trials that focus on cutting-edge therapies and medical technologies. With a commitment to improving patient outcomes, Koite Health Oy leverages a team of experienced professionals and robust methodologies to ensure the highest standards of quality and compliance throughout the research process. By fostering collaborations with healthcare providers and stakeholders, Koite Health Oy aims to bring transformative solutions to the market, enhancing the efficacy and accessibility of treatments for various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampere, Pirkanmaa, Finland
Tampere, Pirkanmaa, Finland
Patients applied
Trial Officials
Tommi Pätilä, Docent
Study Director
Head of Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials